Hiraoka, Atsushi
Kumada, Takashi
Tada, Toshifumi
Tani, Joji
Kariyama, Kazuya
Fukunishi, Shinya
Atsukawa, Masanori
Hirooka, Masashi
Tsuji, Kunihiko
Ishikawa, Toru
Takaguchi, Koichi
Itobayashi, Ei
Tajiri, Kazuto
Shimada, Noritomo
Shibata, Hiroshi
Ochi, Hironori
Kawata, Kazuhito
Yasuda, Satoshi
Toyoda, Hidenori
Aoki, Tomoko
Tanaka, Takaaki
Ohama, Hideko
Nouso, Kazuhiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Arai, Taeang
Okubo, Tomomi
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Joko, Koji
Hiasa, Yoichi
Kudo, Masatoshi
,
Article History
Received: 5 April 2021
Accepted: 16 July 2021
First Online: 17 August 2021
Competing interests
: Atsushi Hiraoka, MD, PhD—Lecture fees: Bayer, Eisai, Eli Lilly, Otsuka. Takashi Kumada, MD, PhD—Lecture fees: Eisai. Masatoshi Kudo, MD, PhD—Advisory role: Eiasi, Ono, MSD, Bristol-Myers Squibb, Roche; Lecture fees: Eisai, Bayer, MSD, Bristol-Myers Squibb, Eli Lilly, EA Pharma; Research funding: Gilead Sciences, Taiho, Sumitomo Dainippon Pharma, Takeda, Otsuka, EA Pharma, Abbvie, Eisai. None of the other authors have potential conflicts of interest to declare.